Investigation of Pharmacokinetics,Safety,and Pharmacodynamics of HRS-5965 in Subjects With Hepatic Impairment

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 26, 2024

Primary Completion Date

March 31, 2025

Study Completion Date

March 31, 2025

Conditions

Complement Mediated Primary or Secondary Glomerular Diseases

Interventions

DRUG

HRS-5965 capsules

Oral 50 mg.

Trial Locations (1)

RECRUITING

The First Affiliated Hospital of Suzhou University, Suzhou

All Listed Sponsors

lead

Chengdu Suncadia Medicine Co., Ltd.

INDUSTRY